Free Trial
NASDAQ:GLUE

Monte Rosa Therapeutics Q2 2024 Earnings Report

Monte Rosa Therapeutics logo
$4.63 +0.04 (+0.78%)
As of 10:15 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Monte Rosa Therapeutics EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Monte Rosa Therapeutics Revenue Results

Actual Revenue
$4.70 million
Expected Revenue
$3.20 million
Beat/Miss
Beat by +$1.50 million
YoY Revenue Growth
N/A

Monte Rosa Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

Monte Rosa Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Monte Rosa Therapeutics Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Monte Rosa Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics (NASDAQ:GLUE), a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

View Monte Rosa Therapeutics Profile

More Earnings Resources from MarketBeat